(Q34805051)

4 August 2017

1 reference

title

Current status of prostaglandin therapy: latanoprost and unoprostone (English)

1 reference

4 August 2017

1 reference

Remo Susanna

1

1 reference

4 August 2017

Paul Chew

series ordinal

2

1 reference

4 August 2017

Yoshiaki Kitazawa

series ordinal

3

1 reference

4 August 2017

language of work or name

1 reference

1 August 2002

1 reference

4 August 2017

published in

Survey of Ophthalmology

1 reference

4 August 2017

volume

47 Suppl 1

1 reference

4 August 2017

page(s)

S97-104

1 reference

Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group.

4 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900308-9

7 January 2021

Latanoprost: experience of 2-year treatment in Scandinavia.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900308-9

7 January 2021

Latanoprost administered once daily caused a maintained reduction of intraocular pressure in glaucoma patients treated concomitantly with timolol

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900308-9

7 January 2021

A randomized double-masked crossover study comparing latanoprost 0.005% with unoprostone 0.12% in patients with primary open-angle glaucoma and ocular hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900308-9

7 January 2021

Comparison of the intraocular pressure-lowering effect of latanoprost and timolol in patients with chronic angle closure glaucoma: a preliminary study

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900308-9

7 January 2021

Cystoid macular edema associated with latanoprost in aphakic and pseudophakic eyes.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900308-9

7 January 2021

Latanoprost-associated cystoid macular edema

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900308-9

7 January 2021

Latanoprost may trigger the biosynthesis of endogenous prostaglandins in early postoperative pseudophakias

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900308-9

7 January 2021

Latanoprost-induced iris color darkening: a case report with long-term follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900308-9

7 January 2021

Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900308-9

7 January 2021

Latanoprost treatment for glaucoma: effects of treating for 1 year and of switching from timolol. United States Latanoprost Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900308-9

7 January 2021

Pilocarpine antagonizes prostaglandin F2 alpha-induced ocular hypotension in monkeys. Evidence for enhancement of Uveoscleral outflow by prostaglandin F2 alpha

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900308-9

7 January 2021

Effect of latanoprost as adjunctive therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900308-9

7 January 2021

The additive intraocular pressure-lowering effect of latanoprost 0.005% daily once and pilocarpine 2% t.i.d. in patients with open-angle glaucoma or ocular hypertension. a 6-month, randomized, multicenter study. German Latanoprost Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900308-9

7 January 2021

Effects of latanoprost on tyrosinase activity and mitotic index of cultured melanoma lines

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900308-9

7 January 2021

Comparison of latanoprost monotherapy to dorzolamide combined with timolol in patients with glaucoma and ocular hypertension.A 3-month randomised study

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900308-9

7 January 2021

The effectiveness of latanoprost for the treatment of pediatric glaucoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900308-9

7 January 2021

Interaction of PhXA41, a new prostaglandin analogue, with pilocarpine. A study on patients with elevated intraocular pressure

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900308-9

7 January 2021

Reduced intraocular pressure and increased ocular perfusion pressure in normal tension glaucoma: a review of short-term studies with three dose regimens of latanoprost treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900308-9

7 January 2021

The fine structure of an iridectomy specimen from a patient with latanoprost-induced eye color change

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900308-9

7 January 2021

Transitory models of experimentally induced intraocular pressure changes in the rabbit. A reappraisal

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900308-9

7 January 2021

A pooled-data analysis of three randomized, double-masked, six-month clinical studies comparing the intraocular pressure reducing effect of latanoprost and timolol.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900308-9

7 January 2021

Efficacy of latanoprost as an adjunct to medical therapy for residual angle-closure glaucoma after iridectomy.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900308-9

7 January 2021

Isopropyl unoprostone increases the activities of matrix metalloproteinases in cultured monkey ciliary muscle cells

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900308-9

7 January 2021

Latanoprost increases the severity and recurrence of herpetic keratitis in the rabbit

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900308-9

7 January 2021

Comparison of 24-hour intraocular pressure reduction with two dosing regimens of latanoprost and timolol maleate in patients with primary open-angle glaucoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900308-9

7 January 2021

Visually significant cystoid macular edema in pseudophakic and aphakic patients with glaucoma receiving latanoprost

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900308-9

7 January 2021

Prostaglandin action on ciliary smooth muscle extracellular matrix metabolism: implications for uveoscleral outflow.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900308-9

7 January 2021

Eyelash formation secondary to latanoprost treatment in a patient with alopecia

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900308-9

7 January 2021

A 12-month, randomized, double-masked study comparing latanoprost with timolol in pigmentary glaucoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900308-9

7 January 2021

The effect of once-daily latanoprost on intraocular pressure and pulsatile ocular blood flow in normal tension glaucoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900308-9

7 January 2021

THE RELATIONSHIP BETWEEN DIURNAL TENSION VARIATION AND THE WATER-DRINKING TEST

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900308-9

7 January 2021

Circadian intraocular pressure management with latanoprost: diurnal and nocturnal intraocular pressure reduction and increased uveoscleral outflow.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900308-9

7 January 2021

A comparison of latanoprost and timolol in primary open-angle glaucoma and ocular hypertension. A 12-week study

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900308-9

7 January 2021

Latanoprost accelerates disruption of the blood-aqueous barrier and the incidence of angiographic cystoid macular edema in early postoperative pseudophakias

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900308-9

7 January 2021

Cystoid macular edema associated with latanoprost therapy in a case series of patients with glaucoma and ocular hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900308-9

7 January 2021

Increased uveoscleral outflow as a possible mechanism of ocular hypotension caused by prostaglandin F2 alpha-1-isopropylester in the cynomolgus monkey.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900308-9

7 January 2021

A comparison of the intraocular pressure-lowering effect of 0.5% timolol maleate and the docosanoid derivative of a PGF2 alpha metabolite, 0.12% unoprostone, in subjects with chronic open-angle glaucoma or ocular hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900308-9

7 January 2021

Comparison of the intraocular pressure lowering effect of latanoprost and a fixed combination of timolol-pilocarpine eye drops in patients insufficiently controlled with beta adrenergic antagonists. French Latanoprost Study Group, and the Swedish La

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900308-9

7 January 2021

A comparison of latanoprost and dorzolamide in patients with glaucoma and ocular hypertension: a 3 month, randomised study. Ireland Latanoprost Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900308-9

7 January 2021

Latanoprost for uncontrolled glaucoma in a compassionate case protocol

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900308-9

7 January 2021

Latanoprost stimulates eumelanogenesis in iridial melanocytes of cynomolgus monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900308-9

7 January 2021

Around-the-clock intraocular pressure reduction with once-daily application of latanoprost by itself or in combination with timolol.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900308-9

7 January 2021

[Latanoprost (Xalatan)-induced macular edema]

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900308-9

7 January 2021

Adverse side effects associated with latanoprost.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900308-9

7 January 2021

Reduction of intraocular pressure with treatment of latanoprost once daily in patients with normal-pressure glaucoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900308-9

7 January 2021

Additive effect of latanoprost, a prostaglandin F2 alpha analogue, and timolol in patients with elevated intraocular pressure

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900308-9

7 January 2021

The mechanism of action of prostaglandins on uveoscleral outflow

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900308-9

7 January 2021

Effect of latanoprost on intraocular pressure in steroid-induced glaucoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900308-9

7 January 2021

Latanoprost and cystoid macular edema: is there a causal relation?

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900308-9

7 January 2021

A comparative study of latanoprost (Xalatan) and isopropyl unoprostone (Rescula) in normal and glaucomatous monkey eyes

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900308-9

7 January 2021

The additive effect of latanoprost to maximum-tolerated medications with low-dose, high-dose, or no pilocarpine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900308-9

7 January 2021

Latanoprost 0.005% and anterior segment uveitis

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900308-9

7 January 2021

Comparison of the efficacy and safety of latanoprost 0.005% compared to brimonidine 0.2% or dorzolamide 2% when added to a topical beta-adrenergic blocker in patients with primary open-angle glaucoma or ocular hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900308-9

7 January 2021

Additive efficacy of unoprostone isopropyl 0.12% (rescula) to latanoprost 0.005%.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900308-9

7 January 2021

A double-masked, randomized clinical trial comparing latanoprost with unoprostone in patients with open-angle glaucoma or ocular hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900308-9

7 January 2021

Efficacy and safety of latanoprost eye drops for glaucoma treatment: a 1-year study in Japan

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900308-9

7 January 2021

Intraocular pressure-lowering efficacy of latanoprost in patients with normal-tension glaucoma or primary open-angle glaucoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900308-9

7 January 2021

CME and anterior uveitis with latanoprost use.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900308-9

7 January 2021

Substituting latanoprost (Xalatan) for isopropyl unoprostone (Rescula) in monotherapy and combination therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900308-9

7 January 2021

Latanoprost and herpes simplex keratitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900308-9

7 January 2021

Latanoprost and cystoid macular oedema in a pseudophake

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900308-9

7 January 2021

Cystoid macular edema and anterior uveitis associated with latanoprost use. Experience and incidence in a retrospective review of 94 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900308-9

7 January 2021

A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. The Latanoprost Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900308-9

7 January 2021

The incidence and time-course of latanoprost-induced iridial pigmentation as a function of eye color.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900308-9

7 January 2021

Use of latanoprost in the treatment of glaucoma associated with Sturge-Weber syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900308-9

7 January 2021

Normal tension glaucoma: the value of predictive tests

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900308-9

7 January 2021

Additive effect of latanoprost to the combination of timolol and dorzolamide.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900308-9

7 January 2021

10.1016/S0039-6257(02)00308-9

Identifiers

DOI

1 reference

4 August 2017

1 reference